Achieve Life Sciences (ACHV) Financials

Achieve Life Sciences, Inc. (ACHV) has a return on equity of -254.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Achieve Life Sciences, Inc. (ACHV) recorded an outflow of $49.5M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Achieve Life Sciences, Inc. (ACHV) recorded an outflow of $49.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Achieve Life Sciences, Inc. (ACHV) had $41.8M in total assets as of fiscal year 2025, including both current and long-term assets.

Achieve Life Sciences, Inc. (ACHV) invested $3K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Achieve Life Sciences, Inc. (ACHV) had 53M shares outstanding as of fiscal year 2025.

Achieve Life Sciences, Inc. (ACHV) had a current ratio of 4.39 as of fiscal year 2025, which is generally considered healthy.

Achieve Life Sciences, Inc. (ACHV) had a debt-to-equity ratio of 0.52 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Achieve Life Sciences, Inc. (ACHV) had a liabilities-to-equity ratio of 0.94 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Achieve Life Sciences, Inc. (ACHV) had a return on assets of -130.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Achieve Life Sciences, Inc. (ACHV) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $674.3M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Achieve Life Sciences, Inc. (ACHV) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $674.3M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Achieve Life Sciences, Inc. (ACHV) held $36.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $49.5M over that year. Dividing the one by the other, the reported balance equals about 9 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Achieve Life Sciences, Inc. (ACHV) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Achieve Life Sciences, Inc. (ACHV) reported a net loss of $54.6M while operations used $49.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.